

Akums launches antibiotic for drug-resistant infections

The combination therapy is designed for severe and life-threatening infections that show limited or no response to conventional antibiotics, particularly in intensive care settings.



New Delhi: Contract Development and Manufacturing Organization (CDMO), Akums Drugs and Pharmaceuticals has launched, Aztreonam-Avibactam injection, an

advanced antibiotic therapy to treat multidrug-resistant gram-negative bacterial infections.

The combination therapy is designed for severe and life-threatening infections that show limited or no response to conventional antibiotics, particularly in intensive care settings.

Akums will manufacture the product at its Kotdwar-based injectable facility in Uttarakhand.

“The rise of antimicrobial resistance has significantly reduced the effectiveness of conventional therapies and Aztreonam-Avibactam represents an important advancement in addressing infections caused by highly resistant pathogens, especially where timely and effective intervention is critical,” said Sanjeev Jain, MD, Akums Drugs and Pharmaceuticals.

News Source:

<https://pharma.economictimes.indiatimes.com/news/drug-approvals-and-launches/akums-launches-antibiotic-for-drug-resistant-infections/130576646>